Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Basket Combination Study to Evaluate Etigilimab in Combination with an Anti-PD-1 in a Series of Tumor Types

X
Trial Profile

A Phase 1b/2 Basket Combination Study to Evaluate Etigilimab in Combination with an Anti-PD-1 in a Series of Tumor Types

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etigilimab (Primary) ; Immune checkpoint protein inhibitors
  • Indications Carcinoma; Cervical cancer; Clear cell sarcoma; Endometrial cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mereo BioPharma
  • Most Recent Events

    • 21 Sep 2023 Status changed from active, no longer recruiting to completed, according to a Mereo BioPharma media release.
    • 07 Sep 2023 According to a Mereo BioPharma media release, R&D expenses relating to etigilimab decreased by 4.4 million pound. The decrease was primarily due to the winding down of the open label Phase 1b/2 basket study in combination with an anti-PD-1 in a range of tumor types.
    • 08 Feb 2023 According to a Mereo BioPharma media release, the company has completed enrollment in this Phase 1b/2 basket study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top